Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 71Prostatic Neoplasms 22Kidney Neoplasms 14Carcinoma, Transitional Cell 9Urinary Bladder Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Urethral Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Urologic Neoplasms 2Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Penile Neoplasms 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Melanoma 2

Interventions

danusertib 1cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Refractory Prostate Cancer × cabozantinib × Genitourinary × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡